^
BIOMARKER:

HER-2 amplification

i
Other names: ERBB2, CD340, HER-2, HER2, NEU, NGL, V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2
Entrez ID:
HER-2 amplification
Breast Cancer
neratinib
Sensitive: A1 - Approval
HER-2 amplification
Hormone Receptor Positive Breast Cancer
Trazimera (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 amplification
HER2 Positive Breast Cancer
Trazimera (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 amplification
Hormone Receptor Positive Breast Cancer
Ontruzant (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 amplification
HER2 Positive Breast Cancer
Ontruzant (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 amplification
Hormone Receptor Positive Breast Cancer
Ogivri (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 amplification
HER2 Positive Breast Cancer
Ogivri (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 amplification
Hormone Receptor Positive Breast Cancer
Kanjinti (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 amplification
HER2 Positive Breast Cancer
Kanjinti (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 amplification
Hormone Receptor Positive Breast Cancer
Herzuma (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 amplification
HER2 Positive Breast Cancer
Herzuma (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 amplification
Hormone Receptor Positive Breast Cancer
neratinib
Sensitive: A1 - Approval
HER-2 amplification
Breast Cancer
Zercepac (trastuzumab biosimilar)
Sensitive: A1 - Approval
HER-2 amplification
CRC
trastuzumab + pertuzumab
Sensitive: A2 - Guideline
HER-2 amplification
CRC
fam-trastuzumab deruxtecan-nxki
Sensitive: A2 - Guideline
HER-2 amplification
CRC
trastuzumab + lapatinib
Sensitive: A2 - Guideline
HER-2 amplification
Rectal Cancer
trastuzumab + pertuzumab
Sensitive: A2 - Guideline
HER-2 amplification
Rectal Cancer
trastuzumab + lapatinib
Sensitive: A2 - Guideline
HER-2 amplification
Rectal Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: A2 - Guideline
HER-2 amplification
Gastric Cancer
trastuzumab
Sensitive: B - Late Trials
HER-2 amplification
HER2 Positive Breast Cancer
trastuzumab
Sensitive: B - Late Trials
HER-2 amplification
Gastroesophageal Junction Adenocarcinoma
trastuzumab
Sensitive: B - Late Trials
HER-2 amplification
Gastric Cancer
lapatinib
Sensitive: B - Late Trials
HER-2 amplification
Breast Cancer
lapatinib
Sensitive: C2 – Inclusion Criteria
HER-2 amplification
Breast Cancer
tucatinib
Sensitive: C2 – Inclusion Criteria
HER-2 amplification
Gastroesophageal Junction Adenocarcinoma
pembrolizumab + trastuzumab
Sensitive: C2 – Inclusion Criteria
HER-2 amplification
Gastric Cancer
pembrolizumab + trastuzumab
Sensitive: C2 – Inclusion Criteria
HER-2 amplification
Breast Cancer
trastuzumab + tucatinib
Sensitive: C2 – Inclusion Criteria
HER-2 amplification
NSCLC
afatinib
Sensitive: C2 – Inclusion Criteria
HER-2 amplification
Urothelial Cancer
afatinib
Sensitive: C2 – Inclusion Criteria
HER-2 amplification
Solid Tumor
pyrotinib
Sensitive: C2 – Inclusion Criteria
HER-2 amplification
HER2 Positive Breast Cancer
trastuzumab + pertuzumab
Sensitive: C2 – Inclusion Criteria
HER-2 amplification
Gastric Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: C2 – Inclusion Criteria
HER-2 amplification
Gastroesophageal Junction Adenocarcinoma
fam-trastuzumab deruxtecan-nxki
Sensitive: C2 – Inclusion Criteria
HER-2 amplification
Esophageal Cancer
ibrutinib
Sensitive: C2 – Inclusion Criteria
HER-2 amplification
Breast Cancer
eFT226
Sensitive: C2 – Inclusion Criteria
HER-2 amplification
Breast Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: C2 – Inclusion Criteria
HER-2 amplification
Gastric Cancer
pembrolizumab
Sensitive: C2 – Inclusion Criteria
HER-2 amplification
HER2 Positive Breast Cancer
avelumab
Sensitive: C2 – Inclusion Criteria
HER-2 amplification
Esophageal Cancer
avelumab
Sensitive: C2 – Inclusion Criteria
HER-2 amplification
HER2 Positive Breast Cancer
HM 78136B
Sensitive: C2 – Inclusion Criteria
HER-2 amplification
Endometrial Cancer
ado-trastuzumab emtansine
Sensitive: C2 – Inclusion Criteria
HER-2 amplification
Lung Cancer
ado-trastuzumab emtansine
Sensitive: C2 – Inclusion Criteria
HER-2 amplification
Gastroesophageal Junction Adenocarcinoma
ado-trastuzumab emtansine
Sensitive: C2 – Inclusion Criteria
HER-2 amplification
Gastric Cancer
ado-trastuzumab emtansine
Sensitive: C2 – Inclusion Criteria
HER-2 amplification
Esophageal Adenocarcinoma
trastuzumab + avelumab
Sensitive: C2 – Inclusion Criteria
HER-2 amplification
Gastric Adenocarcinoma
trastuzumab + avelumab
Sensitive: C2 – Inclusion Criteria
HER-2 amplification
Salivary Gland Cancer
trastuzumab
Sensitive: C2 – Inclusion Criteria
HER-2 amplification
Solid Tumor
SBT6050
Sensitive: C2 – Inclusion Criteria
HER-2 amplification
NSCLC
rivoceranib + pyrotinib
Sensitive: C3 – Early Trials
HER-2 amplification
CRC
panitumumab
Resistant: C3 – Early Trials
HER-2 amplification
Gallbladder Cancer
trastuzumab
Sensitive: C3 – Early Trials
HER-2 amplification
Gallbladder Cancer
lapatinib
Sensitive: C3 – Early Trials
HER-2 amplification
Gallbladder Cancer
trastuzumab + lapatinib
Sensitive: C3 – Early Trials
HER-2 amplification
Cholangiocarcinoma
trastuzumab
Sensitive: C3 – Early Trials
HER-2 amplification
HER2 Positive Breast Cancer
trastuzumab + lapatinib
Sensitive: C3 – Early Trials
HER-2 amplification
Solid Tumor
KN046 + KN026
Sensitive: C3 – Early Trials
HER-2 amplification
Bladder Cancer
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
HER-2 amplification
Biliary Tract Cancer
pyrotinib
Sensitive: C3 – Early Trials
HER-2 amplification
Urothelial Cancer
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
HER-2 amplification
Gastric Cancer
cabazitaxel
Sensitive: C3 – Early Trials
HER-2 amplification
NSCLC
gefitinib
Resistant: C3 – Early Trials
HER-2 amplification
Endometrial Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: C3 – Early Trials
HER-2 amplification
Endometrial Cancer
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
HER-2 amplification
Endometrial Cancer
pyrotinib
Sensitive: C3 – Early Trials
HER-2 amplification
NSCLC
erlotinib
Resistant: C3 – Early Trials
HER-2 amplification
Melanoma
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
HER-2 amplification
NSCLC
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
HER-2 amplification
Salivary Gland Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: C3 – Early Trials
HER-2 amplification
Ovarian Cancer
pyrotinib
Sensitive: C3 – Early Trials
HER-2 amplification
Prostate Cancer
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
HER-2 amplification
Ovarian Cancer
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
HER-2 amplification
Gastroesophageal Junction Adenocarcinoma
pembrolizumab + margetuximab
Sensitive: C3 – Early Trials
HER-2 amplification
LUAD
ado-trastuzumab emtansine
Sensitive: C3 – Early Trials
HER-2 amplification
HER2 Positive Breast Cancer
neratinib + ado-trastuzumab emtansine
Sensitive: C3 – Early Trials
HER-2 amplification
Gastric Cancer
pembrolizumab + margetuximab
Sensitive: C3 – Early Trials
HER-2 amplification
Pancreatic Cancer
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
HER-2 amplification
Salivary Gland Cancer
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
HER-2 amplification
Salivary Gland Cancer
pyrotinib
Sensitive: C3 – Early Trials
HER-2 amplification
NSCLC
dacomitinib
Resistant: C3 – Early Trials
HER-2 amplification
Salivary Gland Cancer
ado-trastuzumab emtansine
Sensitive: C3 – Early Trials
HER-2 amplification
CRC
cetuximab
Resistant: C3 – Early Trials
HER-2 amplification
Ovarian Cancer
ado-trastuzumab emtansine
Sensitive: C3 – Early Trials
HER-2 amplification
Uterine Cancer
ado-trastuzumab emtansine
Sensitive: C3 – Early Trials
HER-2 amplification
Biliary Tract Cancer
ado-trastuzumab emtansine
Sensitive: C3 – Early Trials
HER-2 amplification
Cholangiocarcinoma
ado-trastuzumab emtansine
Sensitive: C3 – Early Trials
HER-2 amplification
Gastric Adenocarcinoma
HER2 inhibitor
Resistant: C3 – Early Trials
HER-2 amplification
Uterine Cancer
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
HER-2 amplification
Solid Tumor
pembrolizumab + SBT6050
Sensitive: C3 – Early Trials
HER-2 amplification
LUAD
pembrolizumab
Sensitive: C4 – Case Studies
HER-2 amplification
Cholangiocarcinoma
pertuzumab/trastuzumab/hyaluronidase-zzxf
Sensitive: C4 – Case Studies
HER-2 amplification
LUAD
afatinib
Sensitive: C4 – Case Studies